20 June 2013
Keywords: gsk, doses, first, patient, ph, iii, syncria
Article | 23 February 2009
UK drug major GlaxoSmithKline has begun patient dosing in the first of five Phase III trials of the investigational glucagon-like ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 February 2009
19 June 2013
© 2013 thepharmaletter.com